BioNexus Gene Lab Corp. 2020 Form 10-K Summary
Business context and reporting period
The filing covers the fiscal year ended December 31, 2020, with comparative results for 2019. BioNexus operates through two Malaysian subsidiaries: BioNexus Malaysia, a molecular diagnostics business using blood-based RNA analysis, and Chemrex Corporation, a wholesaler of industrial and medical chemical materials.
On December 31, 2020, the Company acquired Chemrex from its shareholders in exchange for 68,487,261 common shares. Chemrex was accounted for as a common-control transaction. The 2019 comparative results primarily reflect BioNexus Malaysia, so year-over-year consolidated comparisons are not directly comparable.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $11,390,440 | $126,955 |
| Cost of revenue | $9,670,617 | $71,067 |
| Gross profit | $1,719,823 | $55,888 |
| Gross margin | Approximately 15.1% | Approximately 44.0% |
| Other income | $886,942 | $25,048 |
| General and administrative expense | $1,332,943 | $356,641 |
| Profit/(loss) before tax | $1,262,509 | $(275,705) |
| Net profit/(loss) | $1,094,098 | $(246,469) |
| Net margin | Approximately 9.6% | Not meaningful |
| Cash generated from/(used in) operations | $552,680 | $(217,273) |
| Cash and cash equivalents | $2,787,692 | $859,076 |
| Working capital | $4,611,894 | $830,997 |
| Total liabilities | $3,453,139 | $108,872 |
| Total stockholders’ equity | $6,662,154 | $1,122,364 |
Approximately $11.26 million, or about 98.8% of consolidated revenue, came from Chemrex; BioNexus Malaysia contributed $134,095. Chemrex generated net profit of $1,289,199, while BioNexus Malaysia reported a net loss of $195,101.
Other income included a $706,953 gain on disposal of property. Cash flow also benefited from $1,467,865 of proceeds from the property disposal. Investing activities generated $1,319,990, including the property-sale proceeds, while financing activities used $4,947.
At year-end, current assets were $7,985,494 and current liabilities were $3,373,598, implying a current ratio of approximately 2.4x. The Company had $3,170,653 of trade payables, $60,340 of finance-lease obligations and $63,079 of operating-lease liabilities. The filing does not identify material conventional bank debt.
Material changes versus the prior comparable period
- Consolidated revenue and profitability increased substantially primarily because Chemrex was added to the consolidated business and its operations were reflected in the 2020 financial information.
- The Company shifted from a 2019 net loss of $246,469 to 2020 net profit of $1,094,098.
- Operating cash flow improved from an outflow of $217,273 to an inflow of $552,680.
- Total assets increased from $1,231,236 to $10,115,293, largely reflecting Chemrex’s receivables, inventory, property and cash.
- Common shares outstanding increased from 102,730,891 to 171,218,152, principally through the 68,487,261 shares issued for the Chemrex acquisition.
- BioNexus Malaysia began COVID-19 qPCR testing in the third quarter of 2020. It reported testing more than 5,000 samples and fewer than 100 positive cases for the Ministry of Health.
- BioNexus Malaysia remained loss-making, with 2020 revenue of $134,095 and a net loss of $195,101, while Chemrex accounted for substantially all consolidated earnings.
Guidance, outlook, risks and unusual items
Management expects to continue expanding healthcare-provider relationships, marketing and promotion, corporate screening programs and chemical distribution in Malaysia. BioNexus Malaysia intends to expand into additional Malaysian cities and does not foresee expansion beyond Malaysia until 2021 or later. Management stated that operating cash flow should be sufficient to sustain the current level of operations for at least the next 12 months, but identified potential liquidity uses including additional personnel, marketing, website development and public-company compliance costs.
The National Heart Institute research project for acute myocardial infarction risk prediction is scheduled to continue through December 31, 2021. Management stated that it hoped to develop a gene panel and potentially have the institute incorporate RNA screening into regular processes, but no quantitative revenue guidance was provided.
- COVID-19 created significant operating and economic uncertainty, and the Company stated that it could not quantify the pandemic’s potential impact.
- The blood-screening process has not been supported by broad independent studies, creating efficacy, false-positive and false-negative risks.
- The Company has no product-liability insurance despite potential claims relating to inaccurate diagnoses or patient-information errors.
- Proprietary technology is protected primarily through trade secrets and know-how; the screening process and software are not patent protected.
- The Company may require additional financing for growth, working capital or future operating losses. Additional equity could dilute existing holders.
- Chemrex had three suppliers representing approximately 50% of 2020 cost of sales, creating supplier-concentration risk.
- The Company reported material weaknesses in internal control over financial reporting, including inadequate segregation of duties and the lack of a functioning independent audit committee. Disclosure controls were also deemed ineffective.
- The common stock had no established trading market at the measurement date, and the filing describes limited liquidity and sporadic trading. The Company does not expect to pay cash dividends in the foreseeable future.
Most important facts for investors to verify
- Confirm the accounting and presentation of Chemrex’s results, including the common-control treatment and the extent to which 2020 revenue and earnings represent a full-year contribution.
- Assess the sustainability of Chemrex’s profitability separately from the one-time $706,953 property-disposal gain.
- Review the collectability and aging of the $3,996,802 trade-receivables balance and the liquidity of the $1,176,170 inventory balance.
- Evaluate the remediation status of the disclosed material weaknesses and ineffective disclosure controls.
- Verify the terms, ownership implications and potential dilution associated with the 68,487,261 shares issued for Chemrex.
- Assess independent evidence supporting the accuracy and clinical utility of BioNexus Malaysia’s RNA screening technology.
- Review exposure to product-liability claims, data-privacy breaches, regulatory changes and the absence of product-liability insurance.
- Confirm current trading liquidity, beneficial ownership concentration and the Company’s ability to obtain future financing on acceptable terms.